The DOI matches its Crossref record; the references it cites are not checked yet.
Characteristics of United States Food and Drug Administration Drug Recalls Involving Opioid Medications, 2002–2025
Abstract
Purpose: To characterize the frequency, causes, and severity of opioid medication recalls using United States Food and Drug Administration (FDA) Enforcement Reports. Methods: We conducted a 2002–2025 descriptive analysis of recalls involving seven opioids. FDA free‐text recall reasons were categorized into five standardized domains (wrong dose/potency, contamination, mispackaging/mislabeling, defective delivery system, and quality assurance deviations) by two independent reviewers, with agreement assessed using Cohen's κ (95% CI). Recall severity (Class I–III) was compared across drugs using the chi‐square test, and temporal trends were evaluated with linear regression. Results: We identified 286 opioid‐related recalls, involving over 350 million units. Fentanyl (26.2% of events; > 30 million units), hydromorphone (20.3%; > 11 million), morphine (19.6%; > 73 million), oxycodone (12.6%; > 188 million), and hydrocodone (13.9%; > 50 million) accounted for most events. Recalls of buprenorphine (7.0%; > 3 million) and methadone (3.2%; > 400 thousand) were less frequent. Quality assurance deviations accounted for most recalls (49.5%), followed by mispackaging/mislabeling (14.4%), wrong dose/potency (13.7%), defective delivery systems (12.3%), and contamination (10.1%). Inter‐rater agreement for categorization was high ( κ = 0.88 [0.84–0.93]). Class I recalls (risk of death) comprised 35 events (12.2%), concentrated among fentanyl ( n = 10), morphine ( n = 9), and hydromorphone ( n = 9) ( χ 2 = 43.1, df = 12, p < 0.001). Recall frequency increased significantly over time ( r = 0.63, p = 0.001). Unit count data were missing for 34 events (11.9%), and production denominators were unavailable. Conclusions: Opioid recalls reflect manufacturing or quality assurance problems that may undermine product reliability. More complete recall reporting, including quantitative data, would support efforts to reduce risks associated with pharmaceutical quality failures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
Research works printed but not linked: 20
- 10.1016/j.ijpharm.2016.10.038 · DOI
- 10.1016/j.jpba.2024.116349 · doi:10.1016/j.jpba.2024.116349
- 10.2146/ajhp150277 · DOI
- 10.1001/archinternmed.2012.2013 · DOI
- 10.1371/journal.pone.0109100 · doi:10.1371/journal.pone.0109100
- 10.1016/j.japh.2022.03.010 · doi:10.1016/j.japh.2022.03.010
- 10.1016/j.drudis.2024.103993 · doi:10.1016/j.drudis.2024.103993
- 10.1016/j.japh.2020.07.005 · doi:10.1016/j.japh.2020.07.005
- 10.1208/s12249‐020‐01726‐9 · DOI · Paper page
- 10.1016/j.jpba.2023.115880 · DOI
- 10.1016/j.jaac.2025.05.002 · doi:10.1016/j.jaac.2025.05.002
- 10.1208/s12249‐021‐02165‐w · doi:10.1208/s12249-021-02165-w
- 10.1097/ALN.0000000000004065 · DOI
- 10.1016/j.amepre.2018.01.034 · DOI
- 10.1002/jps.22004 · doi:10.1002/jps.22004
- 10.1001/jamanetworkopen.2022.23708 · DOI
- 10.1007/s13181‐016‐0535‐y · doi:10.1007/s13181-016-0535-y
- 10.1007/s40264‐017‐0572‐8 · DOI
- 10.1007/BF03261989 · doi:10.1007/bf03261989
- 10.1038/s41746‐025‐01642‐x · DOI
Metadata
- Authors
- Nunes, J. C., Costa, G. P. A., & De Aquino, J. P.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2026-02-23
- Volume
- 35
- Issue
- 3
- ISSN
- 1053-8569
- 1099-1557
- Cited by
- 0
- Language
- en
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characteristics of United States Food and Drug Administration Drug Recalls Involving Opioid Medications, 2002–2025. https://app.cochat.ai/papers/10.1002/pds.70341
- The paper
- Nunes, J. C., Costa, G. P. A., & De Aquino, J. P. (2026). Characteristics of United States Food and Drug Administration Drug Recalls Involving Opioid Medications, 2002–2025. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70341
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
